OA11496A - Azabicyclic 5HT1 receptor ligands. - Google Patents

Azabicyclic 5HT1 receptor ligands. Download PDF

Info

Publication number: OA11496A
Authority: OA; OAPI
Prior art keywords: octahydro; benzo; pyrido; disorder; isoxazol
Prior art date: 1998-04-09

Application number

OA1200000273A

Other languages

English (en)

Inventor

Gene Michael Bright

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-09

Filing date

2000-10-06

Publication date

2004-05-14

2000-10-06 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-05-14 Publication of OA11496A publication Critical patent/OA11496A/en

Links

239000003446 ligand Substances 0.000 title description 3
102000035038 5-HT1 receptors Human genes 0.000 title description 2
108091005478 5-HT1 receptors Proteins 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 310
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 186
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 72
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
238000000034 method Methods 0.000 claims description 65
208000035475 disorder Diseases 0.000 claims description 62
239000000203 mixture Substances 0.000 claims description 57
-1 chloro Chemical class 0.000 claims description 37
241000124008 Mammalia Species 0.000 claims description 32
239000003112 inhibitor Substances 0.000 claims description 25
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 claims description 20
229960002073 sertraline Drugs 0.000 claims description 19
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 19
208000018737 Parkinson disease Diseases 0.000 claims description 18
125000000217 alkyl group Chemical group 0.000 claims description 18
229910052757 nitrogen Inorganic materials 0.000 claims description 18
239000000126 substance Substances 0.000 claims description 18
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 17
208000019695 Migraine disease Diseases 0.000 claims description 17
206010028980 Neoplasm Diseases 0.000 claims description 17
201000011510 cancer Diseases 0.000 claims description 17
206010027599 migraine Diseases 0.000 claims description 17
230000000862 serotonergic effect Effects 0.000 claims description 17
230000005062 synaptic transmission Effects 0.000 claims description 16
208000019906 panic disease Diseases 0.000 claims description 15
206010008025 Cerebellar ataxia Diseases 0.000 claims description 14
206010020772 Hypertension Diseases 0.000 claims description 14
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 14
208000002193 Pain Diseases 0.000 claims description 14
206010047163 Vasospasm Diseases 0.000 claims description 14
210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 14
208000019899 phobic disease Diseases 0.000 claims description 14
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims description 13
208000001640 Fibromyalgia Diseases 0.000 claims description 13
208000026139 Memory disease Diseases 0.000 claims description 13
208000008589 Obesity Diseases 0.000 claims description 13
206010036618 Premenstrual syndrome Diseases 0.000 claims description 13
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 13
208000000323 Tourette Syndrome Diseases 0.000 claims description 13
208000016620 Tourette disease Diseases 0.000 claims description 13
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 13
206010023461 kleptomania Diseases 0.000 claims description 13
235000020824 obesity Nutrition 0.000 claims description 13
208000022821 personality disease Diseases 0.000 claims description 13
208000022170 stress incontinence Diseases 0.000 claims description 13
208000006561 Cluster Headache Diseases 0.000 claims description 12
208000030814 Eating disease Diseases 0.000 claims description 12
208000019454 Feeding and Eating disease Diseases 0.000 claims description 12
206010019233 Headaches Diseases 0.000 claims description 12
208000018912 cluster headache syndrome Diseases 0.000 claims description 12
235000014632 disordered eating Nutrition 0.000 claims description 12
208000011580 syndromic disease Diseases 0.000 claims description 12
208000017701 Endocrine disease Diseases 0.000 claims description 11
208000011688 Generalised anxiety disease Diseases 0.000 claims description 11
230000003042 antagnostic effect Effects 0.000 claims description 11
208000022804 avoidant personality disease Diseases 0.000 claims description 11
208000029364 generalized anxiety disease Diseases 0.000 claims description 11
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
229940076279 serotonin Drugs 0.000 claims description 11
208000024891 symptom Diseases 0.000 claims description 11
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 10
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 10
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 10
231100000869 headache Toxicity 0.000 claims description 10
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 10
208000002271 trichotillomania Diseases 0.000 claims description 10
102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 claims description 9
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 9
125000001153 fluoro group Chemical group F* 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
201000001881 impotence Diseases 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
239000003723 serotonin 1A agonist Substances 0.000 claims description 8
239000003727 serotonin 1A antagonist Substances 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
208000019901 Anxiety disease Diseases 0.000 claims description 6
201000001880 Sexual dysfunction Diseases 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
231100000872 sexual dysfunction Toxicity 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
125000005605 benzo group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 4
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims description 4
ONHPOXROAPYCGT-UHFFFAOYSA-N 2,3,4,6,7,8,9,9a-octahydro-1h-pyrido[1,2-a]pyrazine Chemical compound C1CNCC2CCCCN21 ONHPOXROAPYCGT-UHFFFAOYSA-N 0.000 claims description 3
125000001246 bromo group Chemical group Br* 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
125000002346 iodo group Chemical group I* 0.000 claims description 3
125000002950 monocyclic group Chemical group 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
230000002124 endocrine Effects 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000001041 indolyl group Chemical group 0.000 claims description 2
125000001786 isothiazolyl group Chemical group 0.000 claims description 2
125000002971 oxazolyl group Chemical group 0.000 claims description 2
125000005646 oximino group Chemical group 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
125000003373 pyrazinyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
125000001425 triazolyl group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 claims 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
125000004849 alkoxymethyl group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
125000002619 bicyclic group Chemical group 0.000 claims 1
229940125898 compound 5 Drugs 0.000 claims 1
235000005686 eating Nutrition 0.000 claims 1
125000001072 heteroaryl group Chemical group 0.000 claims 1
150000004702 methyl esters Chemical class 0.000 claims 1
230000001314 paroxysmal effect Effects 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 claims 1
239000011593 sulfur Substances 0.000 claims 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 393
229940073584 methylene chloride Drugs 0.000 description 128
239000000243 solution Substances 0.000 description 77
239000002904 solvent Substances 0.000 description 71
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 65
238000006243 chemical reaction Methods 0.000 description 61
239000007787 solid Substances 0.000 description 58
239000000741 silica gel Substances 0.000 description 53
229910002027 silica gel Inorganic materials 0.000 description 53
229960001866 silicon dioxide Drugs 0.000 description 53
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 52
239000000376 reactant Substances 0.000 description 52
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
238000010828 elution Methods 0.000 description 49
238000003818 flash chromatography Methods 0.000 description 48
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
239000000523 sample Substances 0.000 description 38
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
239000012230 colorless oil Substances 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
239000003921 oil Substances 0.000 description 35
235000019198 oils Nutrition 0.000 description 35
239000000284 extract Substances 0.000 description 33
238000005481 NMR spectroscopy Methods 0.000 description 32
239000000047 product Substances 0.000 description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
239000008346 aqueous phase Substances 0.000 description 27
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
235000017557 sodium bicarbonate Nutrition 0.000 description 26
229910000030 sodium bicarbonate Inorganic materials 0.000 description 26
229960001407 sodium bicarbonate Drugs 0.000 description 26
239000011541 reaction mixture Substances 0.000 description 25
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 22
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
239000012458 free base Substances 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 18
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 17
238000004809 thin layer chromatography Methods 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
150000001412 amines Chemical class 0.000 description 16
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 16
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
239000002253 acid Substances 0.000 description 14
239000012455 biphasic mixture Substances 0.000 description 14
239000012312 sodium hydride Substances 0.000 description 14
229910000104 sodium hydride Inorganic materials 0.000 description 14
206010012289 Dementia Diseases 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
229940083608 sodium hydroxide Drugs 0.000 description 12
235000011121 sodium hydroxide Nutrition 0.000 description 12
238000003756 stirring Methods 0.000 description 12
239000000725 suspension Substances 0.000 description 12
229960004132 diethyl ether Drugs 0.000 description 11
235000019441 ethanol Nutrition 0.000 description 11
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
239000012359 Methanesulfonyl chloride Substances 0.000 description 10
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 10
229920006395 saturated elastomer Polymers 0.000 description 10
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 9
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
239000000556 agonist Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
208000008811 Agoraphobia Diseases 0.000 description 8
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
206010041250 Social phobia Diseases 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000012280 lithium aluminium hydride Substances 0.000 description 8
229910000029 sodium carbonate Inorganic materials 0.000 description 8
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 7
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 7
206010012335 Dependence Diseases 0.000 description 7
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 7
206010043118 Tardive Dyskinesia Diseases 0.000 description 7
239000002585 base Substances 0.000 description 7
229960002069 diamorphine Drugs 0.000 description 7
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 7
229940093499 ethyl acetate Drugs 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 7
238000009472 formulation Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
229960002715 nicotine Drugs 0.000 description 7
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
239000012071 phase Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
208000031091 Amnestic disease Diseases 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
101150015707 HTR1A gene Proteins 0.000 description 6
QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 6
208000027089 Parkinsonian disease Diseases 0.000 description 6
206010034010 Parkinsonism Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000001149 cognitive effect Effects 0.000 description 6
208000031424 hyperprolactinemia Diseases 0.000 description 6
238000011065 in-situ storage Methods 0.000 description 6
239000004533 oil dispersion Substances 0.000 description 6
150000002923 oximes Chemical class 0.000 description 6
239000008188 pellet Substances 0.000 description 6
238000010791 quenching Methods 0.000 description 6
230000000171 quenching effect Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
208000019553 vascular disease Diseases 0.000 description 6
NXXMYNTVLHIRDD-UHFFFAOYSA-N 3-chloro-5-fluoro-1,2-benzoxazole Chemical compound FC1=CC=C2ON=C(Cl)C2=C1 NXXMYNTVLHIRDD-UHFFFAOYSA-N 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
206010034912 Phobia Diseases 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 5
239000000935 antidepressant agent Substances 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000006260 foam Substances 0.000 description 5
208000021267 infertility disease Diseases 0.000 description 5
239000003176 neuroleptic agent Substances 0.000 description 5
230000000701 neuroleptic effect Effects 0.000 description 5
239000004001 serotonin 1D antagonist Substances 0.000 description 5
239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 5
208000000587 small cell lung carcinoma Diseases 0.000 description 5
201000001716 specific phobia Diseases 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
102000017911 HTR1A Human genes 0.000 description 4
206010061216 Infarction Diseases 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
230000002051 biphasic effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012065 filter cake Substances 0.000 description 4
239000012467 final product Substances 0.000 description 4
239000007789 gas Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000007574 infarction Effects 0.000 description 4
YKUCHDXIBAQWSF-UHFFFAOYSA-N methyl 3-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1 YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
230000004899 motility Effects 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
229960001779 pargyline Drugs 0.000 description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
INWUFXPCLZRSBH-UHFFFAOYSA-N 3-chloro-1,2-benzoxazole Chemical compound C1=CC=C2C(Cl)=NOC2=C1 INWUFXPCLZRSBH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
206010006550 Bulimia nervosa Diseases 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
206010061428 decreased appetite Diseases 0.000 description 3
150000001983 dialkylethers Chemical class 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000007689 inspection Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
208000028173 post-traumatic stress disease Diseases 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000004537 pulping Methods 0.000 description 3
239000004003 serotonin 1D agonist Substances 0.000 description 3
239000002868 serotonin 5-HT1 receptor antagonist Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
229960003010 sodium sulfate Drugs 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 3
229960003708 sumatriptan Drugs 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
238000001665 trituration Methods 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
ASXGJMSKWNBENU-CQSZACIVSA-N (7R)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C[C@H](N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-CQSZACIVSA-N 0.000 description 2
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 2
WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 2
KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
206010021113 Hypothermia Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
244000309464 bull Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
229960004038 fluvoxamine Drugs 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
229940093956 potassium carbonate Drugs 0.000 description 2
235000011181 potassium carbonates Nutrition 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000010926 purge Methods 0.000 description 2
239000012264 purified product Substances 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
210000003523 substantia nigra Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
ZQZRUVBWUMUFNB-QDEBKDIKSA-N (ne)-n-[(2,3,4-trifluorophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=C(F)C(F)=C1F ZQZRUVBWUMUFNB-QDEBKDIKSA-N 0.000 description 1
0 **(CC1)C=Cc2c1[o]nc2N(CC1)C[C@]2N1C[C@@](CO)CC2 Chemical compound **(CC1)C=Cc2c1[o]nc2N(CC1)C[C@]2N1C[C@@](CO)CC2 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
DZAANUYJOGCNLL-UHFFFAOYSA-N 1-(4-chlorophenyl)propan-2-ylazanium;chloride Chemical compound Cl.CC(N)CC1=CC=C(Cl)C=C1 DZAANUYJOGCNLL-UHFFFAOYSA-N 0.000 description 1
XDYRIGIBUWJCMR-UHFFFAOYSA-N 1-(7-methoxynaphthalen-1-yl)piperazine Chemical compound C12=CC(OC)=CC=C2C=CC=C1N1CCNCC1 XDYRIGIBUWJCMR-UHFFFAOYSA-N 0.000 description 1
GZPMMQGPHXEMSZ-UHFFFAOYSA-N 1-(methoxymethyl)pyrrolidine Chemical compound COCN1CCCC1 GZPMMQGPHXEMSZ-UHFFFAOYSA-N 0.000 description 1
YQMXOIAIYXXXEE-UHFFFAOYSA-N 1-benzylpyrrolidin-3-ol Chemical compound C1C(O)CCN1CC1=CC=CC=C1 YQMXOIAIYXXXEE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
QOMFMQRAFQEKJU-UHFFFAOYSA-N 2,4,4a,5,6,7,8,8a-octahydro-1h-quinazolin-3-ylmethanol Chemical compound C1CCCC2CN(CO)CNC21 QOMFMQRAFQEKJU-UHFFFAOYSA-N 0.000 description 1
KNDAEDDIIQYRHY-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(piperazin-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCNCC1 KNDAEDDIIQYRHY-UHFFFAOYSA-N 0.000 description 1
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 1
WOPSXEFXWDHPLJ-UHFFFAOYSA-N 3-(4-fluorophenyl)-3-[(4-methylphenyl)sulfonylamino]propanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(CC(O)=O)C1=CC=C(F)C=C1 WOPSXEFXWDHPLJ-UHFFFAOYSA-N 0.000 description 1
LHXZWASTUWHFBT-UHFFFAOYSA-N 3-(pyrrolidin-1-ylmethyl)phenol Chemical compound OC1=CC=CC(CN2CCCC2)=C1 LHXZWASTUWHFBT-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
LICHZOBEUWVYSY-UHFFFAOYSA-N 3-azabicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CNC2 LICHZOBEUWVYSY-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
OVWJVIDSGXOFSH-UHFFFAOYSA-N 3-chloro-4-fluoro-1,2-benzoxazole Chemical compound FC1=CC=CC2=C1C(Cl)=NO2 OVWJVIDSGXOFSH-UHFFFAOYSA-N 0.000 description 1
CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
JWPRICQKUNODPZ-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1O JWPRICQKUNODPZ-UHFFFAOYSA-N 0.000 description 1
TVJJJQSAIDKSSM-UHFFFAOYSA-N 5-fluoro-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(F)=CC=C1O TVJJJQSAIDKSSM-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
229940000681 5-hydroxytryptophan Drugs 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
UKFJLHLYPJBMCY-RYUDHWBXSA-N CC(C)(C)OC(N(CC1)C[C@H]2N1C[C@@H](CO)CC2)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]2N1C[C@@H](CO)CC2)=O UKFJLHLYPJBMCY-RYUDHWBXSA-N 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
IUKDDYAECHPPRM-IUCAKERBSA-N OC[C@@H](CC1)CN2[C@@H]1CNCC2 Chemical compound OC[C@@H](CC1)CN2[C@@H]1CNCC2 IUKDDYAECHPPRM-IUCAKERBSA-N 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940125709 anorectic agent Drugs 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000007810 chemical reaction solvent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940121657 clinical drug Drugs 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000012043 crude product Substances 0.000 description 1
IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
229960001270 d- tartaric acid Drugs 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
229960001393 dosulepin Drugs 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940052303 ethers for general anesthesia Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000001530 fumaric acid Chemical class 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000037870 generalized anxiety Diseases 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
239000002035 hexane extract Substances 0.000 description 1
239000013029 homogenous suspension Substances 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960002844 iprindole Drugs 0.000 description 1
PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
229960003587 lisuride Drugs 0.000 description 1
229940006487 lithium cation Drugs 0.000 description 1
229960002813 lofepramine Drugs 0.000 description 1
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229950008693 mesulergine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
GCSINTLJUNXLLU-UHFFFAOYSA-N methyl 3-hydroxy-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(O)=C1 GCSINTLJUNXLLU-UHFFFAOYSA-N 0.000 description 1
229940120152 methyl 3-hydroxybenzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
FUAXXSWWKCVWMD-UHFFFAOYSA-N n,n-dipropyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2C(N(CCC)CCC)CCCC2=C1 FUAXXSWWKCVWMD-UHFFFAOYSA-N 0.000 description 1
SVCQIVUYSQKNAZ-UHFFFAOYSA-N n-[(2,4-difluorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=CC=C(F)C=C1F SVCQIVUYSQKNAZ-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000003880 negative regulation of appetite Effects 0.000 description 1
230000005015 neuronal process Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229960004838 phosphoric acid Drugs 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
CJIVCSBYIRBJSG-UHFFFAOYSA-N pyrrolidine-3,3-diol Chemical compound OC1(O)CCNC1 CJIVCSBYIRBJSG-UHFFFAOYSA-N 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
229940072690 valium Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Luminescent Compositions (AREA)

OA1200000273A 1998-04-09 2000-10-06 Azabicyclic 5HT1 receptor ligands. OA11496A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8123798P	1998-04-09	1998-04-09

Publications (1)

Publication Number	Publication Date
OA11496A true OA11496A (en)	2004-05-14

Family

ID=22162936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000273A OA11496A (en)	1998-04-09	2000-10-06	Azabicyclic 5HT1 receptor ligands.

Country Status (40)

Country	Link
US (2)	US6525048B1 (is)
EP (1)	EP1070065B1 (is)
JP (1)	JP3496759B2 (is)
KR (1)	KR100378931B1 (is)
CN (1)	CN1117092C (is)
AP (1)	AP1175A (is)
AR (1)	AR015751A1 (is)
AT (1)	ATE248838T1 (is)
AU (1)	AU749254B2 (is)
BG (1)	BG104915A (is)
BR (1)	BR9909522A (is)
CA (1)	CA2327782A1 (is)
CO (1)	CO5080727A1 (is)
CZ (1)	CZ20003684A3 (is)
DE (1)	DE69910997T2 (is)
DK (1)	DK1070065T3 (is)
DZ (1)	DZ2756A1 (is)
EA (1)	EA003400B1 (is)
ES (1)	ES2204154T3 (is)
HR (1)	HRP20000653A2 (is)
HU (1)	HUP0102400A3 (is)
ID (1)	ID26086A (is)
IL (1)	IL138629A0 (is)
IS (1)	IS5641A (is)
MA (1)	MA26619A1 (is)
MY (1)	MY133390A (is)
NO (1)	NO20005004L (is)
NZ (1)	NZ507010A (is)
OA (1)	OA11496A (is)
PA (1)	PA8469101A1 (is)
PE (1)	PE20000413A1 (is)
PL (1)	PL343408A1 (is)
PT (1)	PT1070065E (is)
SK (1)	SK14782000A3 (is)
TN (1)	TNSN99056A1 (is)
TR (1)	TR200002932T2 (is)
TW (1)	TW555758B (is)
WO (1)	WO1999052907A1 (is)
YU (1)	YU59400A (is)
ZA (1)	ZA992596B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6231833B1 (en)	1999-08-05	2001-05-15	Pfizer Inc	2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
UA62015C2 (en) *	1998-12-28	2003-12-15	Pfizer Prod Inc	Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
EP1671628B1 (en) *	1999-09-03	2012-10-03	APBI Holdings, LLC	Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB2362826A (en) *	2000-06-02	2001-12-05	Lilly Co Eli	A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
WO2003065970A2 (en) *	2001-02-20	2003-08-14	Royal College Of Surgeons Ie	Treatment of fibromyalgia and related fatigue syndromes using pindolol
BRPI0408248A (pt) *	2003-03-12	2006-03-01	Pfizer Prod Inc	derivados azabicìclicos de piridiloximetila e de benzisoxazol
BRPI0507250A (pt) *	2004-01-29	2007-06-26	Pfizer Prod Inc	combinações para tratar desordens do snc
JP4559749B2 (ja) *	2004-02-16	2010-10-13	あすか製薬株式会社	ピペラジニルピリジン誘導体
AR049478A1 (es)	2004-03-25	2006-08-09	Solvay Pharm Bv	Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) *	2004-03-25	2006-03-29	Solvay Pharm Bv	Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
BRPI0512567A (pt) *	2004-06-22	2008-03-25	Pfizer Prod Inc	compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CA2580042A1 (en) *	2004-09-10	2006-03-16	Pfizer Products Inc.	Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
RU2417082C2 (ru) *	2009-07-14	2011-04-27	Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран)	Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US20210393621A1 (en)	2018-10-26	2021-12-23	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020183011A1 (en)	2019-03-14	2020-09-17	Institut Curie	Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106849A (en) *	1988-05-24	1992-04-21	American Home Products Corporation	Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
WO1990008148A1 (en) *	1989-01-23	1990-07-26	Pfizer Inc.	Bis-aza-bicyclic anxiolytic agents
US5157034A (en) *	1991-02-27	1992-10-20	Pfizer Inc.	Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ES2096099T3 (es) *	1991-09-25	1997-03-01	Pfizer	Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
US5262428A (en) *	1992-03-13	1993-11-16	Wake Forest University	Biologically active tropane derivatives
WO1993025552A1 (en) *	1992-06-16	1993-12-23	Pfizer Inc.	Process and intermediates for bis-aza-bicyclic anxiolytic agents
GB9410512D0 (en) *	1994-05-25	1994-07-13	Smithkline Beecham Plc	Novel treatment
WO1996010570A1 (en) *	1994-09-30	1996-04-11	Pfizer Inc.	NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5614523A (en) *	1995-01-17	1997-03-25	Eli Lilly And Company	Compounds having effects on serotonin-related systems

1999
- 1999-03-17 PA PA19998469101A patent/PA8469101A1/es unknown
- 1999-03-18 TR TR2000/02932T patent/TR200002932T2/xx unknown
- 1999-03-18 KR KR10-2000-7011167A patent/KR100378931B1/ko not_active Expired - Fee Related
- 1999-03-18 WO PCT/IB1999/000457 patent/WO1999052907A1/en not_active Ceased
- 1999-03-18 HR HR20000653A patent/HRP20000653A2/hr not_active Application Discontinuation
- 1999-03-18 YU YU59400A patent/YU59400A/sh unknown
- 1999-03-18 PT PT99945686T patent/PT1070065E/pt unknown
- 1999-03-18 PL PL99343408A patent/PL343408A1/xx not_active Application Discontinuation
- 1999-03-18 NZ NZ507010A patent/NZ507010A/en unknown
- 1999-03-18 ES ES99945686T patent/ES2204154T3/es not_active Expired - Lifetime
- 1999-03-18 US US09/403,892 patent/US6525048B1/en not_active Expired - Fee Related
- 1999-03-18 CN CN99807195A patent/CN1117092C/zh not_active Expired - Fee Related
- 1999-03-18 AU AU32687/99A patent/AU749254B2/en not_active Ceased
- 1999-03-18 EA EA200000910A patent/EA003400B1/ru not_active IP Right Cessation
- 1999-03-18 ID IDW20002017A patent/ID26086A/id unknown
- 1999-03-18 BR BR9909522-0A patent/BR9909522A/pt not_active Application Discontinuation
- 1999-03-18 CA CA002327782A patent/CA2327782A1/en not_active Abandoned
- 1999-03-18 HU HU0102400A patent/HUP0102400A3/hu unknown
- 1999-03-18 IL IL13862999A patent/IL138629A0/xx unknown
- 1999-03-18 DK DK99945686T patent/DK1070065T3/da active
- 1999-03-18 EP EP99945686A patent/EP1070065B1/en not_active Expired - Lifetime
- 1999-03-18 DE DE69910997T patent/DE69910997T2/de not_active Expired - Fee Related
- 1999-03-18 CZ CZ20003684A patent/CZ20003684A3/cs unknown
- 1999-03-18 SK SK1478-2000A patent/SK14782000A3/sk unknown
- 1999-03-18 AT AT99945686T patent/ATE248838T1/de not_active IP Right Cessation
- 1999-03-18 JP JP2000543464A patent/JP3496759B2/ja not_active Expired - Fee Related
- 1999-04-02 TW TW088105301A patent/TW555758B/zh not_active IP Right Cessation
- 1999-04-05 PE PE1999000270A patent/PE20000413A1/es not_active Application Discontinuation
- 1999-04-07 DZ DZ990057A patent/DZ2756A1/xx active
- 1999-04-07 AR ARP990101572A patent/AR015751A1/es unknown
- 1999-04-07 MA MA25527A patent/MA26619A1/fr unknown
- 1999-04-07 TN TNTNSN99056A patent/TNSN99056A1/fr unknown
- 1999-04-07 MY MYPI99001344A patent/MY133390A/en unknown
- 1999-04-08 AP APAP/P/1999/001502A patent/AP1175A/en active
- 1999-04-08 ZA ZA9902596A patent/ZA992596B/xx unknown
- 1999-04-09 CO CO99021093A patent/CO5080727A1/es unknown
2000
- 2000-09-26 IS IS5641A patent/IS5641A/is unknown
- 2000-10-04 NO NO20005004A patent/NO20005004L/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000273A patent/OA11496A/en unknown
- 2000-11-07 BG BG104915A patent/BG104915A/xx unknown
2003
- 2003-02-11 US US10/364,804 patent/US6887905B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1305477A (zh)	2001-07-25
CN1117092C (zh)	2003-08-06
JP3496759B2 (ja)	2004-02-16
NZ507010A (en)	2003-05-30
DZ2756A1 (fr)	2003-09-15
DE69910997T2 (de)	2004-05-19
EA003400B1 (ru)	2003-04-24
KR20010042527A (ko)	2001-05-25
HRP20000653A2 (en)	2001-04-30
WO1999052907A1 (en)	1999-10-21
US6525048B1 (en)	2003-02-25
HUP0102400A2 (hu)	2001-11-28
BR9909522A (pt)	2000-12-19
TR200002932T2 (tr)	2001-01-22
CZ20003684A3 (cs)	2002-03-13
AP9901502A0 (en)	1999-06-30
PA8469101A1 (es)	2000-09-29
DE69910997D1 (de)	2003-10-09
SK14782000A3 (sk)	2002-06-04
KR100378931B1 (ko)	2003-04-07
PT1070065E (pt)	2003-12-31
NO20005004L (no)	2000-11-27
BG104915A (en)	2001-07-31
US20030181458A1 (en)	2003-09-25
YU59400A (sh)	2003-10-31
AU3268799A (en)	1999-11-01
AP1175A (en)	2003-06-04
PL343408A1 (en)	2001-08-13
DK1070065T3 (da)	2003-11-24
EA200000910A1 (ru)	2001-04-23
ID26086A (id)	2000-11-23
JP2002511469A (ja)	2002-04-16
NO20005004D0 (no)	2000-10-04
IL138629A0 (en)	2001-10-31
EP1070065B1 (en)	2003-09-03
PE20000413A1 (es)	2000-05-25
TW555758B (en)	2003-10-01
ZA992596B (en)	2000-10-08
US6887905B2 (en)	2005-05-03
HK1035719A1 (en)	2001-12-07
ES2204154T3 (es)	2004-04-16
CA2327782A1 (en)	1999-10-21
AR015751A1 (es)	2001-05-16
MY133390A (en)	2007-11-30
AU749254B2 (en)	2002-06-20
HUP0102400A3 (en)	2002-10-28
MA26619A1 (fr)	2004-12-20
TNSN99056A1 (fr)	2005-11-10
ATE248838T1 (de)	2003-09-15
CO5080727A1 (es)	2001-09-25
EP1070065A1 (en)	2001-01-24
IS5641A (is)	2000-09-26

Publication	Publication Date	Title
EP1070065B1 (en)	2003-09-03	Azabicyclic 5ht1 receptor ligands
US6602874B2 (en)	2003-08-05	Heterocyclic carboxamides
US7345038B2 (en)	2008-03-18	Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
EP1140931B1 (en)	2004-02-25	5ht1 antagonists for antidepressant therapy
RS59400B1 (sr)	2019-11-29	O-alkil-benzilidengvanidinski derivati i terapijska upotreba za lečenje poremećaja povezanih sa akumulacijom pogrešno savijenih proteina
EP1113015B1 (en)	2004-09-15	Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
MXPA00009854A (en)	2001-07-09	Azabicyclic 5ht1 receptor ligands
US20050227981A1 (en)	2005-10-13	Aralkyl and aralkylidene heterocyclic lactam and imides
US20050227980A1 (en)	2005-10-13	Aralkyl and aralkylidene heterocyclic lactam and imides
MXPA01006669A (en)	2002-03-26	5ht1 antagonists for antidepressant therapy
HK1040395A (en)	2002-06-07	5ht1 antagonists for antidepressant therapy